COVID-19 and Vaccination Status in Lysosomal Storage Diseases: A Single-Center Experience
dc.authorscopusid | 58181536600 | |
dc.authorscopusid | 23059712400 | |
dc.authorscopusid | 57202984757 | |
dc.authorscopusid | 58183170500 | |
dc.authorscopusid | 57731091200 | |
dc.authorscopusid | 35749318700 | |
dc.authorscopusid | 26428601400 | |
dc.contributor.author | Yoldaş, Çelik, M. | |
dc.contributor.author | Canda, E. | |
dc.contributor.author | Yazıcı, H. | |
dc.contributor.author | Erdem, F. | |
dc.contributor.author | Özkaya, P.Y. | |
dc.contributor.author | Sahbudak, Z.B. | |
dc.contributor.author | Uçar, S.K. | |
dc.date.accessioned | 2024-08-25T18:51:52Z | |
dc.date.available | 2024-08-25T18:51:52Z | |
dc.date.issued | 2023 | |
dc.department | Ege Üniversitesi | en_US |
dc.description.abstract | Objective: Coronavirus disease 2019 (COVID-19) causes significant morbidity and mortality in individuals with chronic disease. There is not enough information about the course of corona-virus disease in lysosomal storage diseases. This study aimed to evaluate coronavirus disease vaccination status and the impact of coronavirus disease on lysosomal storage disease. Materials and Methods: The study included 87 lysosomal storage disease patients. The patients’ diagnoses were Gaucher, mucopolysaccharidosis I, II, IVA, VI, VII, Fabry, and Pompe. A questionnaire assessing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure, coronavirus disease symptoms, and vaccine status was administered in person or by phone calls. Results: The number of coronavirus disease positive patients was 8 (9.1%). Only 2 patients were treated in the intensive care unit. Other coronavirus disease patients had mild symptoms and stayed in-home quarantine. Patients over 12 years of age could receive a COVID-19 vaccine. 63.5% of those aged ?12 years were vaccinated. Conclusion: Lysosomal storage disease patients did not have an increased risk of COVID-19 compared to the healthy population, despite the chronic inflammatory disease. Vaccination of lysosomal storage disease patients will be protective against severe coronavirus disease. © 2023, AVES. All rights reserved. | en_US |
dc.identifier.doi | 10.5152/TurkArchPediatr.2023.22233 | |
dc.identifier.endpage | 267 | en_US |
dc.identifier.issn | 2757-6256 | |
dc.identifier.issue | 3 | en_US |
dc.identifier.scopus | 2-s2.0-85160523823 | en_US |
dc.identifier.scopusquality | Q3 | en_US |
dc.identifier.startpage | 262 | en_US |
dc.identifier.trdizinid | 1179221 | en_US |
dc.identifier.uri | https://doi.org/10.5152/TurkArchPediatr.2023.22233 | |
dc.identifier.uri | https://search.trdizin.gov.tr/tr/yayin/detay/1179221 | |
dc.identifier.uri | https://hdl.handle.net/11454/102741 | |
dc.identifier.volume | 58 | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | TR-Dizin | en_US |
dc.language.iso | en | en_US |
dc.publisher | AVES | en_US |
dc.relation.ispartof | Turkish Archives of Pediatrics | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.snmz | 20240825_G | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | fabry | en_US |
dc.subject | Gaucher | en_US |
dc.subject | inherited metabolic diseases | en_US |
dc.subject | lysosomal storage diseases | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | coronavac | en_US |
dc.subject | favipiravir | en_US |
dc.subject | immunoglobulin | en_US |
dc.subject | steroid | en_US |
dc.subject | tenofovir | en_US |
dc.subject | adolescent | en_US |
dc.subject | adult | en_US |
dc.subject | anosmia | en_US |
dc.subject | Article | en_US |
dc.subject | child | en_US |
dc.subject | clinical article | en_US |
dc.subject | coronavirus disease 2019 | en_US |
dc.subject | diabetes mellitus | en_US |
dc.subject | Fabry disease | en_US |
dc.subject | female | en_US |
dc.subject | Gaucher disease | en_US |
dc.subject | headache | en_US |
dc.subject | hospitalization | en_US |
dc.subject | human | en_US |
dc.subject | hypertension | en_US |
dc.subject | inflammatory disease | en_US |
dc.subject | intensive care unit | en_US |
dc.subject | leukopenia | en_US |
dc.subject | liver disease | en_US |
dc.subject | lung disease | en_US |
dc.subject | lysosome storage disease | en_US |
dc.subject | male | en_US |
dc.subject | morbidity | en_US |
dc.subject | mortality | en_US |
dc.subject | mucopolysaccharidosis | en_US |
dc.subject | nose smear | en_US |
dc.subject | obesity | en_US |
dc.subject | pneumonia | en_US |
dc.subject | polymerase chain reaction | en_US |
dc.subject | questionnaire | en_US |
dc.subject | sore throat | en_US |
dc.subject | thrombocytopenia | en_US |
dc.subject | vaccination | en_US |
dc.title | COVID-19 and Vaccination Status in Lysosomal Storage Diseases: A Single-Center Experience | en_US |
dc.type | Article | en_US |